[go: up one dir, main page]

MX2014006396A - Vacunas contra el virus de la influenza y sus usos. - Google Patents

Vacunas contra el virus de la influenza y sus usos.

Info

Publication number
MX2014006396A
MX2014006396A MX2014006396A MX2014006396A MX2014006396A MX 2014006396 A MX2014006396 A MX 2014006396A MX 2014006396 A MX2014006396 A MX 2014006396A MX 2014006396 A MX2014006396 A MX 2014006396A MX 2014006396 A MX2014006396 A MX 2014006396A
Authority
MX
Mexico
Prior art keywords
polypeptides
domain
influenza virus
influenza hemagglutinin
virus vaccines
Prior art date
Application number
MX2014006396A
Other languages
English (en)
Other versions
MX357009B (es
Inventor
Wilem Meijberg Jan
Impagliazzo Antonietta
Vogels Ronald
Heinz Edward Friesen Robert
Alard Philippe
Loverix Stefan
Radosevic Katarina
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of MX2014006396A publication Critical patent/MX2014006396A/es
Publication of MX357009B publication Critical patent/MX357009B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C07K16/108—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Polipéptidos que comprenden polipéptidos del dominio de tallo de la hemaglutinina de la influenza, donde dichos polipéptidos comprenden (a) un dominio HA1 de la hemaglutinina de la influenza, que comprende un segmento del tallo N-terminal del HA1, unido covalentemente mediante una secuencia conectora de 0-50 aminoácidos a un segmento del tallo C-terminal del HA1, y (b) un dominio HA2 de la hemaglutinina de la influenza en el que se han mutado uno o más aminoácidos. También se proveen ácidos nucleicos que codifican dichos polipéptidos, composiciones que comprenden a los polipéptidos y/o a las moléculas de ácidos nucleicos; así como métodos para usarlos, en particular en la detección, la prevención y/o el tratamiento de la influenza.
MX2014006396A 2011-11-28 2012-11-27 Vacunas contra el virus de la influenza y sus usos. MX357009B (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161564086P 2011-11-28 2011-11-28
US201161564198P 2011-11-28 2011-11-28
EP11191003 2011-11-28
EP11191009 2011-11-28
EP12166268 2012-05-01
US201261720281P 2012-10-30 2012-10-30
PCT/EP2012/073706 WO2013079473A1 (en) 2011-11-28 2012-11-27 Influenza virus vaccines and uses thereof

Publications (2)

Publication Number Publication Date
MX2014006396A true MX2014006396A (es) 2014-07-22
MX357009B MX357009B (es) 2018-06-22

Family

ID=48534691

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014006396A MX357009B (es) 2011-11-28 2012-11-27 Vacunas contra el virus de la influenza y sus usos.

Country Status (20)

Country Link
US (3) US9452211B2 (es)
EP (2) EP3566714A1 (es)
JP (1) JP6294828B2 (es)
KR (1) KR101983989B1 (es)
CN (1) CN104066446B (es)
AR (1) AR089005A1 (es)
AU (1) AU2012343981B2 (es)
BR (1) BR112014012681A8 (es)
CA (1) CA2857087C (es)
EA (1) EA033386B1 (es)
HK (1) HK1199211A1 (es)
IL (1) IL232780A (es)
IN (1) IN2014CN04742A (es)
MX (1) MX357009B (es)
MY (1) MY170927A (es)
PH (1) PH12014501118B1 (es)
SG (1) SG11201402633UA (es)
TW (1) TWI618715B (es)
WO (1) WO2013079473A1 (es)
ZA (1) ZA201404797B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3009145A1 (en) 2009-03-30 2016-04-20 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
BR112012020839A2 (pt) 2010-02-18 2017-11-21 Sinai School Medicine vacinas para uso na profilaxe e tratamento de doença de vírus da influenza
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
EP4241785B1 (en) 2011-09-20 2026-01-28 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
MY170927A (en) 2011-11-28 2019-09-19 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
JP2015519348A (ja) * 2012-05-23 2015-07-09 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ インフルエンザワクチン構築物
CA2895508A1 (en) 2012-12-18 2014-06-26 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
EP3004142B1 (en) * 2013-05-30 2020-09-30 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
EP3805254A1 (en) * 2013-08-03 2021-04-14 Calder Biosciences Inc. Methods of making and using influenza virus hemagglutinin complexes
WO2015166329A1 (en) * 2014-05-01 2015-11-05 Indian Institute Of Science Polypeptides for generating anti-influenza antibodies and uses thereof
WO2015197820A1 (en) 2014-06-26 2015-12-30 Crucell Holland B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
IL249704B (en) * 2014-07-10 2021-03-25 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
US10111944B2 (en) * 2014-07-10 2018-10-30 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
KR102463632B1 (ko) * 2014-07-10 2022-11-03 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 바이러스 백신 및 이의 용도
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
US10738083B2 (en) * 2015-05-11 2020-08-11 Janssen Vaccines & Prevention B.V. Influenza virus neutralizing peptidomimetic compounds
EP4019044A3 (en) 2015-09-02 2022-08-24 Janssen Vaccines & Prevention B.V. Stabilized viral class i fusion proteins
EP3471767A4 (en) 2016-06-15 2020-01-15 Icahn School of Medicine at Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
IL303650B2 (en) 2016-09-02 2025-02-01 Us Health Stable group 2 trimers from the stem region of influenza hemagglutinin and their uses
CN110325208A (zh) * 2016-09-16 2019-10-11 威克斯技术公司 针对流感的疫苗接种的组合物和方法
WO2018075592A1 (en) * 2016-10-21 2018-04-26 Merck Sharp & Dohme Corp. Influenza hemagglutinin protein vaccines
WO2018187706A2 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
CA3076263C (en) * 2017-11-22 2023-12-19 Her Majesty the Queen in the Right of Canada as represented by the Minister of Health Synthetic hemagglutinin as universal vaccine against infection by type b influenza viruses (ibv)
CN111556896A (zh) * 2017-12-21 2020-08-18 株式会社绿色生物医药 交叉免疫抗原疫苗及其制备方法
PE20210651A1 (es) 2018-01-23 2021-03-26 Janssen Vaccines And Prevention B V Vacunas contra virus de la gripe y usos de las mismas
WO2019246363A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
US12139511B2 (en) 2018-06-27 2024-11-12 Aramis Biotechnologies Inc. Influenza virus hemagglutinin mutants
BR112021020907A2 (pt) * 2019-04-25 2022-04-19 Janssen Vaccines & Prevention Bv Antígenos de influenza recombinantes
AU2020342463A1 (en) * 2019-09-05 2022-03-24 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
EP4045517A2 (en) * 2019-10-15 2022-08-24 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
EP4146241A4 (en) * 2020-05-08 2024-06-05 Academia Sinica CHIMERIC INFLUENZA VACCINES
US20230310575A1 (en) * 2020-09-02 2023-10-05 St. Jude Children's Research Hospital, Inc. Hemagglutinin Modifications for Improved Influenza Vaccine Production
MX2023002674A (es) 2020-09-07 2023-04-03 Intervet Int Bv Vacuna del tallo de ha para blancos positivos a anticuerpos ha.
MX2023015327A (es) * 2021-06-28 2024-01-23 Glaxosmithkline Biologicals Sa Antigenos de la influenza novedosos.
CA3264702A1 (en) * 2022-08-16 2024-02-22 Seqirus Inc. MODIFIED FLU VIRUSES
CN116589566A (zh) * 2022-11-18 2023-08-15 昆明医科大学第一附属医院 一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用
CN116874607B (zh) * 2023-06-09 2024-12-10 山西高等创新研究院 一种h9亚型禽流感重组嵌合疫苗及其制备方法
CN116947982B (zh) * 2023-07-12 2024-05-14 吉林大学 三条优势表位肽序列及其在流感病毒疫苗的应用
WO2025038983A1 (en) * 2023-08-17 2025-02-20 Colorado State University Research Foundation Inactivated whole virion vaccine against influenza and methods of use thereof
WO2025149907A1 (en) * 2024-01-08 2025-07-17 Seqirus Inc. Influenza vaccines

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
JP3037554B2 (ja) * 1993-04-20 2000-04-24 寳酒造株式会社 免疫原性人工ポリペプチド
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6413776B1 (en) 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6248780B1 (en) 1998-10-01 2001-06-19 Duquesne University Of The Holy Ghost Compounds for the treatment of estrogen-dependent illnesses and methods for making and using the same
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6869936B1 (en) 1999-03-04 2005-03-22 Crucell Holland B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
CA2418977C (en) 2000-08-10 2011-01-18 Crucell Holland B.V. Gene delivery vectors with cell type specificity for primary human chondrocytes
US6905678B2 (en) 2001-07-07 2005-06-14 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells
KR101006594B1 (ko) 2002-04-25 2011-01-07 크루셀 홀란드 비.브이. 안정한 아데노바이러스 벡터 및 그 증식 방법
MXPA04008891A (es) 2002-04-25 2004-11-26 Crucell Holland Bv Medios y metodos para la produccion de vectores de adenovirus.
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
EP1553983A2 (en) 2002-10-23 2005-07-20 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
US20050221493A1 (en) 2002-12-04 2005-10-06 Crucell Holland B.V. Recombinant virus production for the manufacturing of vaccines
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
HRP20130616T1 (en) 2003-10-02 2013-08-31 Crucell Holland B.V. Packaging cells for recombinant adenovirus
CN101090974B (zh) 2004-11-16 2011-05-11 克鲁塞尔荷兰公司 包含重组病毒载体的多价疫苗
EA017203B1 (ru) 2006-09-07 2012-10-30 Круселл Холланд Б.В. Связывающие молекулы человека, способные нейтрализовать вирус гриппа h5n1, и их применение
EP3009145A1 (en) * 2009-03-30 2016-04-20 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
CA2761648C (en) 2009-05-11 2019-03-12 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
CN102939103A (zh) * 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
US9168292B2 (en) 2010-09-27 2015-10-27 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
WO2013007770A1 (en) 2011-07-14 2013-01-17 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses
EP2780034A1 (en) 2011-11-14 2014-09-24 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
MY170927A (en) 2011-11-28 2019-09-19 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
US20130236494A1 (en) 2012-03-06 2013-09-12 Crucell Holland B.V. Vaccination against influenza
EP2822968B1 (en) 2012-03-08 2018-01-10 Janssen Vaccines & Prevention B.V. Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
CA2884388A1 (en) 2012-09-27 2014-04-03 Crucell Holland B.V. Human binding molecules capable of binding to and neutralizing hepatitis b viruses and uses thereof
EP3004142B1 (en) 2013-05-30 2020-09-30 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
US10111944B2 (en) 2014-07-10 2018-10-30 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
KR102463632B1 (ko) 2014-07-10 2022-11-03 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 바이러스 백신 및 이의 용도

Also Published As

Publication number Publication date
CN104066446B (zh) 2017-10-03
MX357009B (es) 2018-06-22
PH12014501118B1 (en) 2019-03-01
EP2785372B1 (en) 2019-06-19
WO2013079473A1 (en) 2013-06-06
US20140357845A1 (en) 2014-12-04
CA2857087A1 (en) 2013-06-06
KR101983989B1 (ko) 2019-05-31
MY170927A (en) 2019-09-19
HK1199211A1 (en) 2015-06-26
US20160362455A1 (en) 2016-12-15
PH12014501118A1 (en) 2014-08-04
US9969778B2 (en) 2018-05-15
AU2012343981A1 (en) 2014-07-10
CA2857087C (en) 2021-05-25
CN104066446A (zh) 2014-09-24
EA201491051A1 (ru) 2015-04-30
IL232780A (en) 2017-09-28
BR112014012681A2 (pt) 2017-06-13
US20160355553A1 (en) 2016-12-08
SG11201402633UA (en) 2014-09-26
US9452211B2 (en) 2016-09-27
IN2014CN04742A (es) 2015-09-18
JP6294828B2 (ja) 2018-03-14
BR112014012681A8 (pt) 2017-06-20
NZ625973A (en) 2016-09-30
EA033386B1 (ru) 2019-10-31
IL232780A0 (en) 2014-07-31
AR089005A1 (es) 2014-07-23
TW201329101A (zh) 2013-07-16
EP3566714A1 (en) 2019-11-13
ZA201404797B (en) 2022-03-30
EP2785372A1 (en) 2014-10-08
KR20140099515A (ko) 2014-08-12
TWI618715B (zh) 2018-03-21
JP2015502353A (ja) 2015-01-22
AU2012343981B2 (en) 2017-09-07

Similar Documents

Publication Publication Date Title
MX2014006396A (es) Vacunas contra el virus de la influenza y sus usos.
EA201591164A1 (ru) Вакцины против вируса гриппа и их применение
EA201692467A1 (ru) Вакцины против вируса гриппа и их применения
CO6680702A2 (es) Péptido o complejo péptido que se une a integrina alfa 2 y metodos y sus usos que implican a los mismos
CY1122824T1 (el) Πρωτεϊνες συντηξης και εμβολια συνδυασμου
ES2682981T3 (es) Proteínas de hemaglutinina del virus de la gripe y método de uso de las mismas
EA201692541A1 (ru) Вакцины против вируса гриппа и их применения
MX2016013034A (es) Composicion detergente.
MX2014010755A (es) Moleculas de union humanas que pueden unirse a los virus de la influenza b y neutralizarlos, y sus usos.
MX387336B (es) Enzimas de clostridium histolyticum y metodos para el uso de los mismos.
CO6210831A2 (es) Nuevas proteinas h5 moleculas de acido nucleico y vectores que las codifican y su uso medicinal
EA201590860A1 (ru) Варианты гемагглютинина и нейраминидазы вируса свиного гриппа
CL2020001901A1 (es) Vacunas contra virus de la gripe y usos de las mismas.
AR102950A1 (es) Variantes de lipasa y polinucleótidos que las codifican
MX371403B (es) Moleculas de andamiaje a base de fibronectina estabilizada.
MX390924B (es) Detergentes y agentes de limpieza que comprenden una combinación de amilasa y proteasa.
CO2017012675A2 (es) Péptidos lipidados resistentes a proteasas
BR112016019390A2 (pt) proteínas de fusão uti
BR112015004629A2 (pt) polipeptídeos de clostridium difficile como vacinas
AR102061A1 (es) Genes de chromobacterium subtsugae
MX2018001298A (es) Agente inductor de inmunidad.
AR094846A1 (es) Proteínas h5 del virus de la gripe h5n1 para uso como un medicamento
CU20140061A7 (es) Vacunas contra virus influenza y sus usos
SG10201908920QA (en) Influenza virus vaccines and uses thereof
MX2017002621A (es) Vacuna.

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: SANDVIK HYPERION AB

FG Grant or registration